Home | Current Issue | Past Issues | Search | CollectionsRSS | PDA Services | FAQ | SHCIM Online | Chinese Updated Tuesday, November 20, 2018
 Services
Submit a manuscript
Subscribe
Individuals
Institutions
Response
Send response
Read responses
Reprint
Advance online publication
Sign up for e-alert
JCIM job opportunities
Contact JCIM
 Information For
Readers
Authors
Reviewers
Advertisers
 About JCIM
Journal description
Editorial policy
Privacy policy
Copy right
Editorial staff
 Language Polishing
Journal of Chinese Integrative Medicine: 2015; 13(4): 262–268
DOI: 10.1016/S2095-4964(15)60185-6
Immunomodulation and liver protection of Yinchenhao decoction against concanavalin A-induced chronic liver injury in mice
1. Shi-li Jiang (Department of Liver Cirrhosis, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China )
2. Xu-dong Hu (Department of Biology, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China )
3. Ping Liu (E-institute of Shanghai Municipal Education Committee, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China )

ABSTRACT

OBJECTIVE: This study investigated the immunoregulatory and protective roles of Yinchenhao decoction, a compound of Chinese herbal medicine, in a mouse model of concanavalin A (ConA)-induced chronic liver injury.

METHODS: Female BalB/c mice were randomly divided into 4 groups: normal control, ConA model, ConA model treated with Yinchenhao decoction (400 mg/kg, orally), and ConA model treated with dexamethasone (0.5 mg/kg, orally). All treatments were given once a day for 28 d. Except of the normal control, mice received tail vein injection of ConA (10 mg/kg) on days 7, 14, 21, and 28, at 1 h after treatment with Yinchenhao decoction or dexamethasone or saline to induce chronic liver injury.

RESULTS: Repeated ConA injection induced chronic liver injury, which was evidenced by inflammatory cell infiltration and necrosis, increased serum alanine aminotranferease activities, decreased albumin levels, and an imbalanced expression of immunoregulatory genes in the liver tissues including significantly enhanced interferon-γ, interleukin-4, monocyte chemotactic protein-1, and cluster of differentiation 163 mRNA levels, and reduced tumor necrosis factor-α and interleukin-6 mRNA levels. Treatment with Yinchenhao decoction significantly reversed the ConA-induced changes in immunoregulatory gene expression in the liver tissues, reduced serum alanine aminotranferease activity, enhanced serum albumin level, and attenuated the extent of liver inflammation and necrosis. Furthermore, Yinchenhao decoction did not result in hepatocyte degeneration and spleen weight loss that were observed in mice received long-term treatment with dexamethasone.

CONCLUSION: Yinchenhao decoction treatment protected liver against the ConA-induced chronic liver damage and improved liver function, which were associated with the modulation of gene expression related to immune/inflammatory response.

Welcome to JCIM! You are the number 5448 reader of this article!
Download Article:
[Full Text]      [PDF]      [Chinese]      [Previous]      [Next]      [This Issue]
Please cite this article as:
Jiang SL, Hu XD, Liu P. Immunomodulation and liver protection of Yinchenhao decoction against concanavalin A-induced chronic liver Injury in mice. J Integr Med. 2015; 13(4): 262–268.
References:
1Manns MP, Czaja AJ, Gorham JD, Krawitt EL, Mieli-Vergani G, Vergani D, Vierling JM; American Association for the Study of Liver Diseases. Diagnosis and management of autoimmune hepatitis[J].Hepatology, 2010, 51(6): 2193–2213.  .
2Strassburg CP, Manns MP. Therapy of autoimmune hepatitis[J].Best Pract Res Clin Gastroenterol, 2011, 25(6): 673–687.  .
3Yamashiki M, Mase A, Arai I, Huang XX, Nobori T, Nishimura A, Sakaguchi S, Inoue K. Effects of the Japanese herbal medicine ‘Inchinko-to’ (TJ-135) on concanavalin A-induced hepatitis in mice[J].Clin Sci (Lond), 2000, 99(5): 421–431.  .
4Cai H, Song YH, Xia WJ, Jin MW. Aqueous extract of Yin-Chen-Hao decoction, a traditional Chinese prescription, exerts protective effects on concanavalin A-induced hepatitis in mice through inhibition of NF-κB[J].J Pharm Pharmacol, 2006, 58(5): 677–684.  .
5Tiegs G, Hentschel L, Wendel A. A T cell-dependent experimental liver injury in mice inducible by concanavalin A[J].J Clin Invest, 1992, 90(1): 196–203.  .
6Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kiernan TW, Wollman J. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis[J].Hepatology, 1981, 1(5): 431–435.  .
7Wang TL, Liu X, Zhou ZP, He JW, Zhang J, Li NZ, Duan ZP, Wang BE. A semiquantitative scoring system for assessment of hepatic inflammation and fibrosis in chronic viral hepatitis[J].Zhonghua Gan Zang Bing Za Zhi, 1998, 66(4): 195–197.  .
8Kimura K, Ando K, Ohnishi H, Ishikawa T, Kakumu S, Takemura M, Muto Y, Moriwaki H. Immunopathogenesis of hepatic fibrosis in chronic liver injury induced by repeatedly administered concanavalin A[J].Int Immunol, 1999, 11(9): 1491–1500.  .
9Liu C, Sun M, Wang L, Wang G, Chen G, Liu C, Liu P. Effects of Yinchenhao Tang and related decoctions on DMN-induced cirrhosis/fibrosis in rats[J].Chin Med, 2008, 3: 1.  .
10Carr MW, Roth SJ, Luther E, Rose SS, Springer TA. Monocyte chemoattractant protein 1 acts as a T-lymphocyte chemoattractant[J].Proc Natl Acad Sci U S A, 1994, 91(9): 3652–3656.  .
11Czaja AJ. Review article: chemokines as orchestrators of autoimmune hepatitis and potential therapeutic targets[J].Aliment Pharmacol Ther, 2014, 40(3): 261–279.  .
12Teoh N, Field J, Sutton J, Farrell G. Dual role of tumor necrosis factor-α in hepatic ischemia-reperfusion injury: studies in tumor necrosis factor-α gene knockout mice[J].Hepatology, 2004, 39(2): 412–421.  .
13Streetz KL, Tacke F, Leifeld L, Wüstefeld T, Graw A, Klein C, Kamino K, Spengler U, Kreipe H, Kubicka S, Müller W, Manns MP, Trautwein C. Interleukin 6/gp130-dependent pathways are protective during chronic liver diseases[J].Hepatology, 2003, 38(1): 218–229.  .
14Klein C, Wüstefeld T, Assmus U, Roskams T, Rose-John S, Müller M, Manns MP, Ernst M, Trautwein C. The IL-6-gp130-STAT3 pathway in hepatocytes triggers liver protection in T cell-mediated liver injury[J].J Clin Invest, 2005, 115(4): 860–869.  .
15Lutz HH, Sackett SD, Kroy DC, Gassler N, Trautwein C. Deletion of gp130 in myeloid cells modulates IL-6-release and is associated with more severe liver injury of Con A hepatitis[J].Eur J Cell Biol, 2012, 91(6–7): 576–581.  .
16Lee JD, Rhoades K, Economou JS. Interleukin-4 inhibits the expression of tumour necrosis factors α and β, interleukins-1β and -6 and interferon-γ[J].Immunol Cell Biol, 1995, 73(1): 57–61.  .
17Camargo CA Jr, Madden JF, Gao W, Selvan RS, Clavien PA. Interleukin-6 protects liver against warm ischemia/reperfusion injury and promotes hepatocyte proliferation in the rodent[J].Hepatology, 1997, 26(6): 1513–1520.  .
18Loyer P, Ilyin G, Abdel Razzak Z, Banchereau J, Dezier JF, Campion JP, Guguen-Guillouzo C, Guillouzo A. Interleukin 4 inhibits the production of some acute-phase proteins by human hepatocytes in primary culture[J].FEBS Lett, 1993, 336(2): 215–220.  .
19Van Gorp H, Delputte PL, Nauwynck HJ. Scavenger receptor CD163, a Jack-of-all-trades and potential target for cell-directed therapy[J].Mol Immunol, 2010, 47(7–8): 1650–1660.  .

 Home | Current Issue | Past Issues | Search | CollectionsRSS | PDA Services | FAQ | SHCIM Online | Chinese
Copyright © 2003-2012 by JCIM Press. All rights reserved. ISSN 1672-1977